Capital Analysts LLC Sells 81,991 Shares of Zoetis Inc. $ZTS

Posted by Brenda Bartman on Aug 16th, 2026

Capital Analysts LLC reduced its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 99.0% during the second quarter, Holdings Channel.com reports. The firm owned 787 shares of the company’s stock after selling 81,991 shares during the period. Capital Analysts LLC’s holdings in Zoetis were worth $56,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Prosperity Bancshares Inc purchased a new position in shares of Zoetis in the fourth quarter valued at about $25,000. University of Texas Texas AM Investment Management Co. purchased a new stake in Zoetis in the 2nd quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC purchased a new stake in Zoetis in the 1st quarter worth approximately $28,000. Root Financial Partners LLC grew its position in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after buying an additional 103 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter worth approximately $32,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS opened at $73.64 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market cap of $30.43 billion, a price-to-earnings ratio of 12.13, a price-to-earnings-growth ratio of 1.28 and a beta of 0.74. The stock has a fifty day simple moving average of $76.30 and a two-hundred day simple moving average of $99.01. Zoetis Inc. has a 12-month low of $71.45 and a 12-month high of $160.48.

Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s quarterly revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts predict that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.9%. Zoetis’s dividend payout ratio (DPR) is currently 34.93%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. Stifel Nicolaus decreased their target price on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Piper Sandler cut their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a report on Monday, August 10th. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. JPMorgan Chase & Co. dropped their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $109.62.

Check Out Our Latest Stock Report on Zoetis

About Zoetis

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Capital Analysts LLC Sells 81,991 Shares of Zoetis Inc. $ZTS

Zoetis Price Performance

Zoetis Dividend Announcement

Wall Street Analysts Forecast Growth

About Zoetis

See Also

You might be interested in: